Category: Acceleron

  • Acceleron investors dig their heels in on Merck takeover bid

    Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the company. Avoro Capital, Holocene Advisors and Darwin Global are all arguing that Acceleron should hold off on a sale for several upcoming developments that they maintain could dramatically increase vale. […]

  • PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

    BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma Published: Oct 1, 2021 | Tags: BMS, EMA, MAA, Relatlimab, Nivolumab, Metastatic Melanoma Merck and Ridgeback Report Interim Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 Published: Oct 1, 2021 | Tags: Merck, […]

  • PharmaShots’ Key Highlights of Third Quarter 2021

    The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B, […]

  • Merck to Acquire Acceleron for ~$11.5B

    Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected to close in Q4’21 The acquisition will strengthen Merck’s cardiovascular pipeline. Acceleron’s sotatercept is currently in P-III trials & has the potential to improve short-term […]

  • Merck confirms $11.5bn Acceleron takeover deal

    After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far. The $180-per-share deal – if completed – will give Merck a pair of blockbuster drug candidates, one of which is already […]

  • Rumour mill says Acceleron is speeding towards $11bn sale

    US biopharma company Acceleron is the next company heading for a takeover by a big pharma group – according to a Bloomberg report citing people close to the matter. Rumours of a deal have been bubbling away for a few days, driving Acceleron’s stock upwards, even before Bloomberg reported that a large pharma group is […]

  • EHA21: Study raises BMS’ hopes for Reblozyl in less severe disease

    Bristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after hitting the target in a phase 2 trial in patients who don’t require regular blood transfusions.  Reblozyl (luspatercept) is already approved to treat thalassaemia patients who depend on transfusions, but getting approval in patients with milder disease […]

  • PharmaShots Weekly Snapshots (Mar 29 – Apr 02, 2021)

    Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19 Published: Apr 2, 2021 | Tags: Pfizer and BioNTech, Report, Results, BNT162b2, Prevent, COVID-19 Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM Published: Apr 2, 2021 | Tags: Acceleron, Presents, Results, Sotatercept, P-II PULSAR […]

  • PharmaShots Weekly Snapshots (Feb 15- 19, 2021)

    RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204  Published: Feb 19, 2021 | Tags: RedHill, Signs, Manufacturing, Agreement, Cosmo, Movantik, RHB-204 Astellas and Seagen Reports Submission of Two BLA to the US FDA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer Published: Feb 19, 2021 | Tags: Astellas, Seagen, Reports, Submission, […]

  • Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

    Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional payments $143.5M for all subsequent products commercialized plus royalties on sales of product Acceleron to get rights to access Fulcrum’s product engine and target identification platform for identifying small molecule […]